REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone240-552-8181
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$218.51 million
Profitability
Miscellaneous
Employees192
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Regenxbio (NASDAQ:RGNX) Frequently Asked Questions
What is Regenxbio's stock symbol?
Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."
How were Regenxbio's earnings last quarter?
Regenxbio Inc (NASDAQ:RGNX) issued its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.85) by $0.04. The biotechnology company earned $0.88 million during the quarter. Regenxbio had a negative return on equity of 9.90% and a negative net margin of 41.99%. View Regenxbio's Earnings History.
When is Regenxbio's next earnings date?
What price target have analysts set for RGNX?
7 analysts have issued twelve-month price objectives for Regenxbio's shares. Their predictions range from $42.00 to $145.00. On average, they expect Regenxbio's share price to reach $84.1786 in the next year. This suggests a possible upside of 63.7% from the stock's current price. View Analyst Price Targets for Regenxbio.
What is the consensus analysts' recommendation for Regenxbio?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.
Has Regenxbio been receiving favorable news coverage?
News headlines about RGNX stock have trended somewhat positive on Monday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Regenxbio earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Regenxbio.
Who are some of Regenxbio's key competitors?
Some companies that are related to Regenxbio include bluebird bio (BLUE), argenx (ARGX), Ablynx (ABLYF), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Repligen (RGEN), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Aerie Pharmaceuticals (AERI) and Alector (ALEC).
What other stocks do shareholders of Regenxbio own?
Who are Regenxbio's key executives?
Regenxbio's management team includes the folowing people:
- Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)
- Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)
- Mr. Curran M. Simpson, Sr. VP of Product Devel. & Chief Technology Officer (Age 57)
- Dr. Olivier Danos, Chief Scientific Officer (Age 61)
- Dr. Stephen Yoo, Consultant (Age 41)
Who are Regenxbio's major shareholders?
Regenxbio's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.32%), Redmile Group LLC (3.88%), JPMorgan Chase & Co. (3.29%), FMR LLC (2.36%), Botty Investors LLC (0.66%) and SG Americas Securities LLC (0.49%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.
Which institutional investors are selling Regenxbio stock?
RGNX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, James Investment Research Inc., ClariVest Asset Management LLC, Strs Ohio, Rhumbline Advisers, American International Group Inc., Ipswich Investment Management Co. Inc. and Victory Capital Management Inc.. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Insider Buying and Selling for Regenxbio.
Which institutional investors are buying Regenxbio stock?
RGNX stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, JPMorgan Chase & Co., Acadian Asset Management LLC, Pier Capital LLC, Redmile Group LLC, BlackRock Inc., GAM Holding AG and P.A.W. Capital Corp. View Insider Buying and Selling for Regenxbio.
How do I buy shares of Regenxbio?
Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regenxbio's stock price today?
One share of RGNX stock can currently be purchased for approximately $51.43.
How big of a company is Regenxbio?
Regenxbio has a market capitalization of $1.88 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis. Regenxbio employs 192 workers across the globe.View Additional Information About Regenxbio.
What is Regenxbio's official website?
How can I contact Regenxbio?
Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]
MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
